Novel vascular endothelial growth factor blocker improves cellular viability and reduces hypobaric hypoxia-induced vascular leakage and oedema in rat brain

Clinical and Experimental Pharmacology & Physiology
Deepika SaraswatSiva Prasad Cvs

Abstract

Vascular endothelial growth factor (VEGF) is an important cerebral angiogenic and permeability factor under hypoxia. There is a need to find effective molecules that may ameliorate hypoxia-induced cerebral oedema. In silico identification of novel candidate molecules that block VEGF-A site were identified and validated with a Ramachandran plot. The active site residues of VEGF-A were detected by Pocketfinder, CASTp, and DogSiteScorer. Based on in silico data, three VEGF-A blocker (VAB) candidate molecules (VAB1, VAB2, and VAB3) were checked for improvement in cellular viability and regulation of VEGF levels in N2a cells under hypoxia (0.5% O2 ). Additionally, the best candidate molecule's efficacy was assessed in male Sprague-Dawley rats for its ameliorative effect on cerebral oedema and vascular leakage under hypobaric hypoxia 7260 m. All experimental results were compared with the commercially available VEGF blocker sunitinib. Vascular endothelial growth factor-A blocker 1 was found most effective in increasing cellular viability and maintaining normal VEGF levels under hypoxia (0.5% oxygen) in N2a cells. Vascular endothelial growth factor-A blocker 1 effectively restored VEGF levels, decreased cerebral oedema, and reduced va...Continue Reading

References

Jul 4, 1990·Journal of the National Cancer Institute·P SkehanM R Boyd
Aug 17, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·B MeisterR Möhle
Feb 8, 2000·Biological Chemistry·P ScheideggerR Jaussi
Aug 22, 2001·European Journal of Applied Physiology·R WalterW H Reinhart
Oct 23, 2002·Brain : a Journal of Neurology·Heike J SchochHugo H Marti
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jun 13, 2003·Lancet·Buddha Basnyat, David R Murdoch
Sep 19, 2003·Trends in Biochemical Sciences·Michael J CrossLena Claesson-Welsh
May 28, 2004·Emergency Medicine Clinics of North America·Scott A Gallagher, Peter H Hackett
Jul 22, 2004·High Altitude Medicine & Biology·Peter H Hackett, Robert C Roach
Sep 29, 2004·Journal of Clinical Pathology·A E Greijer, E van der Wall
Jan 1, 2005·Current Opinion in Oncology·Evert C A Kaal, Charles J Vecht
Jan 26, 2005·Journal of Chemical Information and Modeling·John J Irwin, Brian K Shoichet
Mar 11, 2005·Molecular & Cellular Proteomics : MCP·Jianghong AnRuben Abagyan
Jun 23, 2006·Acta Crystallographica. Section D, Biological Crystallography·S WlodekA Nicholls
Feb 1, 2008·Investigative Ophthalmology & Visual Science·Lanlan YuNapoleone Ferrara
Apr 1, 2009·Nature Reviews. Clinical Oncology·Elizabeth R GerstnerTracy T Batchelor
Feb 18, 2011·Journal of Chemical Information and Modeling·Mark McGann
Mar 3, 2011·Current Opinion in Chemical Biology·Norelle L Daly, David J Craik
Jun 7, 2012·Journal of Computer-aided Molecular Design·Mark McGann
Jul 5, 2012·The Keio Journal of Medicine·Yoshiaki Kubota
Dec 1, 2004·Drug Discovery Today. Technologies·Christopher A Lipinski

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.